Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase III Trial of Herceptin Followed by Chemotherapy Plus Herceptin Versus the Combination of Herceptin and Chemotherapy as Palliative Treatment in Patients With HER2-Overexpressing Advanced/Metastatic Breast Cancer

Trial Profile

Randomized Phase III Trial of Herceptin Followed by Chemotherapy Plus Herceptin Versus the Combination of Herceptin and Chemotherapy as Palliative Treatment in Patients With HER2-Overexpressing Advanced/Metastatic Breast Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Trastuzumab (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 Dec 2016 Results published in the Annals of Oncology
    • 08 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top